# Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)

> **NCT00666198** · — · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 3337 (actual)

## Conditions studied

- Pulmonary Hypertension

## Interventions

- **DRUG:** SILDENAFIL

## Key facts

- **NCT ID:** NCT00666198
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 3337 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00666198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00666198, "Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00666198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*